A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer

NCT05145218 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

405

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Platinum-resistant Ovarian Cancer

Interventions

DRUG: Anlotinib Hydrochloride Capsules
DRUG: Paclitaxel injection
DRUG: TQB2450 injection

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.